NCT06205732招募中不适用
Retrospective Study and Construction of a Prediction Model for Patients With Intermediate and Advanced Liver Cancer Treated With TACE Combined With Immunotherapy and Targeted Therapy
Qianfoshan Hospital1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2024年1月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Progression-Free-Survival
研究概览
简要总结
To evaluate the effectiveness of TACE combined with immunotherapy and targeted therapy versus TACE alone in patients with intermediate and advanced liver cancer.
详细描述
To evaluate the efficacy and safety of TACE combined with immunotherapy and targeted therapy in patients with intermediate and advanced liver cancer. Explore the factors affecting the prognosis of liver cancer treated with TACE combined with immunotherapy and targeted therapy and establish a specific individualized prognostic score and risk stratification model.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥18 years old, both men and women
- •primary liver cancer confirmed by liver biopsy or history of hepatitis B, AFP, and typical imaging findings
- •patients with liver function Child-Pugh A or B (≤8 points)
- •BCLC stage B and stage C
- •expected survival time ≥8 weeks
- •patients with generally good performance status (ECOG PS score 0 or 1)
排除标准
- •The patient's key data is missing
- •liver metastatic cancer confirmed by histology or cytology
- •patients who interrupt treatment due to intolerance of adverse drug reactions
- •combined with primary malignant tumors of other organs within 5 years; combined with other serious diseases, such as severe heart disease, renal insufficiency, severe infection, bleeding, etc.
- •combined with systemic infection, autoimmune disease, or other types of tumors; previous allogeneic bone marrow transplantation or solid organ transplantation
- •study participants known to have mental illness
- •situations such as drug use or substance abuse
结局指标
主要结局
Progression-Free-Survival
时间窗: 12 months
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Survival Analysis: TACE vs. Combination Therapy in HCCHepatocellular CarcinomaNCT06261138Zhejiang University279
Unknown
不适用
TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic CholangiocarcinomaIntrahepatic CholangiocarcinomaNCT05247996The Central Hospital of Lishui City98
尚未招募
不适用
Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world StudyHCCNCT06024252Zhongda Hospital200
Unknown
不适用
Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using TACE With AntiangiogenesisHepatocellular CarcinomaNCT00518557Southeast University, China60
已完成
2 期
Combination Immunotherapy and Autologous Stem Cell Transplantation for MyelomaMyelomaNCT01245673University of Pennsylvania28